Literature DB >> 28024890

Assessment of cell viability and permeation enhancement in presence of lipid-based self-emulsifying drug delivery systems using Caco-2 cell model: Polysorbate 80 as the surfactant.

Pengli Bu1, Yue Ji2, Silpa Narayanan3, Damon Dalrymple4, Xingguo Cheng3, Abu T M Serajuddin5.   

Abstract

PURPOSE: Lipid-based self-emulsifying drug delivery systems (SEDDS) are commonly used for solubilizing and enhancing oral bioavailability of poorly water-soluble drugs. However, their effects on viability of intestine epithelial cells and influence on membrane permeation are poorly understood. The present study was undertaken for safety assessment of lipid-based formulations containing medium-chain fatty acid esters as lipids and polysorbate 80 as the surfactant using the Caco-2 in vitro model. Any possible paracellular permeation enhancement through Caco-2 monolayers by the nontoxic formulations was also investigated.
METHODS: Mixtures of monoglyceride (Capmul MCM EP or 708G) or propylene glycol monoester (Capmul PG-8 NF) of medium chain fatty acids with polysorbate 80, with and without the incorporation of a medium-chain triglyceride (Captex 355), were prepared. After suitable dilution with aqueous culture medium, the formulations were incubated with a series of Caco-2 cultures of different maturity. Cell viability and membrane integrity were assessed. Any effects of nontoxic formulations on the transport of the fluorescent dye, Lucifer yellow, through Caco-2 monolayers were also determined.
RESULTS: Formulations containing 1:1 ratios of monoglyceride or propylene glycol monoester to triglyceride (30% polysorbate 80, 35% monoglyceride or monoester and 35% triglyceride) were best tolerated by Caco-2 cells. Increased maturity obtained through longer culture durations rendered Caco-2 cells greater tolerance towards lipid-based formulations, and maximum tolerance to lipid-based formulations was observed with Caco-2 monolayers after being cultured for 21-23days. Furthermore, extent of cell membrane rupture caused by lipid-surfactant mixtures correlated positively with levels of cytotoxicity, suggesting a potential underlying mechanism. Permeation studies using Caco-2 monolayer model revealed that certain formulations significantly enhanced paracellular transport activities.
CONCLUSIONS: Lipid-based SEDDS containing mixtures of monoglyceride (or monoester) and triglyceride of medium chain fatty acids formed fine microemulsions and were significantly less toxic than other formulations. Fully differentiated Caco-2 monolayer was more resistant to lipid-surfactant mixtures than less mature cultures. Certain formulations were also capable of enhancing paracellular permeation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Caco-2 cells; Cytotoxicity; Lipid-based drug delivery system; Medium-chain lipid; Monoglyceride; Permeation enhancement; Polysorbate 80; Propylene glycol monoester; Surfactant; Triglyceride

Mesh:

Substances:

Year:  2016        PMID: 28024890     DOI: 10.1016/j.ejps.2016.12.018

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

1.  Suitability of Artificial Membranes in Lipolysis-Permeation Assays of Oral Lipid-Based Formulations.

Authors:  Oliver J Hedge; Christel A S Bergström
Journal:  Pharm Res       Date:  2020-05-20       Impact factor: 4.200

2.  Interaction between Different Pharmaceutical Excipients in Liquid Dosage Forms-Assessment of Cytotoxicity and Antimicrobial Activity.

Authors:  Dániel Nemes; Renátó Kovács; Fruzsina Nagy; Mirtill Mező; Nikolett Poczok; Zoltán Ujhelyi; Ágota Pető; Pálma Fehér; Ferenc Fenyvesi; Judit Váradi; Miklós Vecsernyés; Ildikó Bácskay
Journal:  Molecules       Date:  2018-07-23       Impact factor: 4.411

3.  Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments.

Authors:  Aroha B Sánchez; Ana C Calpena; Mireia Mallandrich; Beatriz Clares
Journal:  Pharmaceutics       Date:  2019-11-29       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.